301075.SZ
多瑞医药
SZSE · C 制造业 · CN
CNY 53.75
+0.09%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 137.2M | 154.2M | 240.6M | 334.3M | 401.0M |
| Cost of Revenue | 130.4M | 141.6M | 138.6M | 105.1M | 92.3M |
| Gross Profit | 6.8M | 12.6M | 102.1M | 229.2M | 308.7M |
| Operating Expenses | |||||
| R&D Expense | 31.5M | 32.4M | 37.0M | 24.0M | 26.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 57.7M | 56.9M | 54.2M | 40.3M | 41.9M |
| Selling & Marketing Expense | 15.1M | 23.1M | 80.9M | 161.8M | 230.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 123.9M | 132.7M | 177.4M | 225.5M | 296.1M |
| Cost and Expenses | 254.3M | 274.3M | 316.0M | 330.6M | 388.5M |
| Operating Income (EBIT) | (124.5M) | (128.4M) | (85.8M) | 22.2M | 21.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (127.5M) | (131.4M) | (85.8M) | 22.2M | 21.0M |
| Income Tax Expense | 1.2M | 1.0M | (746.2K) | 5.2M | 2.4M |
| Bottom Line | |||||
| Net Income | (100.5M) | (102.2M) | (62.7M) | 18.9M | 20.5M |
| Earnings from Cont. Ops | (128.7M) | (132.4M) | (85.0M) | 17.1M | 18.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (100.5M) | (102.2M) | (62.7M) | 18.9M | 20.5M |
| Per Share | |||||
| Basic EPS | (CN¥1.28) | (CN¥1.29) | (CN¥0.79) | CN¥0.24 | CN¥0.26 |
| Diluted EPS | (CN¥1.28) | (CN¥1.29) | (CN¥0.79) | CN¥0.24 | CN¥0.26 |
| Revenue Per Share | CN¥1.77 | CN¥1.95 | CN¥3.03 | CN¥4.26 | CN¥5.09 |
| Shares | |||||
| Basic Shares Outstanding | 77.6M | 79.2M | 79.3M | 78.5M | 78.9M |
| Diluted Shares Outstanding | 77.6M | 79.2M | 79.3M | 78.5M | 78.9M |
| Profitability Metrics | |||||
| EBITDA | — | (78.9M) | (58.6M) | 40.9M | 37.0M |
| D&A | — | 49.5M | 27.2M | 18.7M | 15.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026